BioCentury
ARTICLE | Clinical News

Gilead reports additional Phase III data from HIV switching trial of Biktarvy

March 9, 2018 7:58 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) reported additional data from the Phase III GS-US-380-1844 trial in 563 virologically suppressed adults with HIV-1 infection showing that switching from either Tivicay dolutegravir plus abacavir/lamivudine or Triumeq dolutegravir/abacavir/lamivudine to once-daily 50/200/25 mg Biktarvy bictegravir/emtricitabine/tenofovir alafenamide led to a rate of virologic failure at week 48, the primary endpoint, of 1.1% vs. 0.4% for patients remaining on Tivicay plus abacavir/lamivudine or Triumeq (p=0.62). Virologic failure was defined as HIV-1 RNA levels of ≥50 copies/mL.

Additionally, 93.6% of patients who switched to Biktarvy achieved HIV-1 RNA levels of <50 copies/mL at week 48, a secondary endpoint, vs. 95% of patients who remained on Tivicay plus abacavir/lamivudine or Triumeq. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Boston...

BCIQ Company Profiles

Gilead Sciences Inc.